Company Profile
Recursion Stock Price, News & Analysis
- Ticker:
- RXRX
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
3.18 USD (+0.32%)
Close
Last updated: August 6, 2026
1.92B USD
Market cap
Why the stock is moving
Following the latest company update, “Recursion Reports Second Quarter Financial Results; Genentech Options First Neuroscience Target into Early Discovery Program”, RXRX closed down 4.23% at $3.17 on Aug 5, 2026. The move occurred in the trading session associated with this earnings update.
Company overview
AI-Native Drug Discovery
Recursion is a clinical-stage TechBio company using an integrated discovery and development platform to generate medicines across oncology, rare disease, neuroscience and immunology. The Recursion OS combines proprietary multimodal biological and chemical data, purpose-built AI models and experimental validation.
REC-1245
REC-1245 is a potential first-in-class RBM39 degrader being evaluated in the Phase 1/2 DAHLIA study for solid tumors. Early dose-escalation results showed predictable pharmacokinetics and no dose-limiting toxicities, supporting continued evaluation of monotherapy expansion doses.
REC-4881
REC-4881 is a MEK1/2 inhibitor in Phase 2 development for familial adenomatous polyposis. Recursion has observed efficacy signals and has begun discussions with the FDA regarding a potential registrational development path.
REC-4539
REC-4539 is a selective, brain-penetrant and reversible LSD1 inhibitor in Phase 1 development for solid tumors and acute myeloid leukemia. Its reversible mechanism is intended to reduce the platelet toxicity associated with sustained LSD1 inhibition.
Platform-Derived Portfolio
The company advances both wholly owned and partnered candidates, using clinical programs as validation points for the speed and translational potential of its AI-enabled platform. REC-1245, for example, moved from biological discovery to a development candidate in approximately 18 months.
Future catalysts
Regulatory update on the potential registrational path for REC-4881 expected in the second half of 2026.
Additional Phase 1 dose-escalation data for REC-1245 expected in the second half of 2026.
Additional Phase 1b/2 clinical data for REC-4881 expected in the first half of 2027.
Recent news
- 01
- 02
- 03
Recursion to Participate in Upcoming Investor Conferences
Source: Recursion
- 04
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Recursion (RXRX)?
Recursion (RXRX) most recently closed at 3.18 USD, a +0.32% move versus the previous session.
What is the market cap of Recursion (RXRX)?
Recursion currently has a market capitalization of 1.92B USD on BioPharmSignal.
What does Recursion do?
AI-Native Drug Discovery Recursion is a clinical-stage TechBio company using an integrated discovery and development platform to generate medicines across oncology, rare disease, neuroscience and immunology. The Recursion OS combines proprietary multimodal biological and chemical data, purpose-built AI models and experimental validation. REC-1245 REC-1245...
On which exchange is RXRX stock listed?
Recursion (RXRX) is associated with NASDAQ, United States, Biopharma.
What is REC-1245?
Additional Phase 1 dose-escalation data for REC-1245 expected in the second half of 2026.
Which conditions is Recursion targeting with REC-1245?
Recursion is associated with oncology, immunology, rare disease based on its company overview and current catalyst commentary.
How does Recursion describe recent progress with REC-1245?
Additional Phase 1 dose-escalation data for REC-1245 expected in the second half of 2026.
What is REC-4881?
REC-4881 REC-4881 is a MEK1/2 inhibitor in Phase 2 development for familial adenomatous polyposis.